Principia Announces Proposed Public Offering of Common Stock
October 15, 2019 16:02 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune...
Principia Announces Positive Preliminary Data of PRN1008 for Immune Thrombocytopenia in Ongoing Phase 1/2 Trial
October 15, 2019 07:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Oct. 15, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company focused on developing novel therapies for immune mediated...
Principia Announces Positive Preliminary Data of PRN1008 from its Ongoing Phase 2 Part B Trial in Pemphigus
October 10, 2019 07:00 ET
|
Principia Biopharma Inc.
Consistent efficacy and safety profile for pemphigus patients observed Confirms 400mg twice daily dose in Phase 3 trial Principia to host investor conference call at 8:00 am Eastern time SOUTH...
Principia Biopharma Appoints Shawn Tomasello to Its Board of Directors
August 30, 2019 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia to Present at the 2019 Baird Global Healthcare Conference and the Wells Fargo Healthcare Conference
August 27, 2019 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 27, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Reports Second Quarter Financial Results
August 08, 2019 16:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., Aug. 08, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Announces Update to Ongoing Phase 2 Clinical Trial in Patients with ITP
July 30, 2019 08:01 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., July 30, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Biopharma Appoints Patrick Machado to Board of Directors
June 11, 2019 16:05 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., June 11, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...
Principia Presents Phase 1 Data of PRN1371 in Patients with Metastatic Bladder Cancer
May 20, 2019 08:00 ET
|
Principia Biopharma Inc.
-- FGFR inhibitor PRN1371 well tolerated in 36 patients in dose-escalation phase; dose expansion in metastatic urothelial carcinoma patients ongoing -- SOUTH SAN FRANCISCO, Calif., May 20, 2019 ...
Principia Biopharma Announces First Patient Dosed in Sanofi’s Phase 2b Trial of SAR442168 in Multiple Sclerosis, Triggering $30 Million Milestone
May 14, 2019 16:05 ET
|
Principia Biopharma Inc.
SOUTH SAN FRANCISCO, Calif., May 14, 2019 (GLOBE NEWSWIRE) -- Principia Biopharma Inc. (Nasdaq: PRNB), a late-stage biopharmaceutical company dedicated to bringing transformative oral therapies to...